Key result
AI improves early detection and risk prediction in ischemic heart disease over standard diagnostic tools.
Why the study?
Ischemic heart disease remains a leading cause of global morbidity and mortality, while conventional diagnostic methods face limitations such as delayed biomarker elevation, reliance on expert interpretation, and variability.
Does artificial intelligence improve early detection, diagnostic accuracy, and risk prediction of ischemic heart disease compared with conventional diagnostic and risk assessment methods?
Does artificial intelligence improve early detection, diagnostic accuracy, and risk prediction of ischemic heart disease compared with conventional diagnostic and risk assessment methods?
This cross-modality structured narrative review highlights that while AI substantially improves diagnostic speed and precision for ischemic heart disease across ECG, imaging, and biomarkers, widespread clinical adoption requires prospective multicenter trials, external validation, and equitable dataset representation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
May support AI for ischemic heart disease detection; leaves open clinical adoption pending prospective validation.
Ischemic heart disease (IHD) remains a leading cause of global morbidity and mortality, underscoring the need for rapid and accurate diagnostic strategies. Conventional methods, including electrocardiography (ECG), imaging, and biomarkers, are effective but limited by factors such as delayed biomarker elevation, reliance on expert interpretation, and variability across settings. Artificial intelligence (AI) offers new opportunities to enhance early detection and risk prediction by applying machine learning and deep learning to large, complex datasets. In ECG analysis, AI models consistently identify subtle ischemic patterns, including occlusive myocardial infarction, with accuracy that often rivals or exceeds clinicians. In imaging, AI enhances echocardiography, CT, MRI, and nuclear modalities by automating segmentation, strain analysis, and plaque quantification while reducing interpretation time. In biomarkers, AI augments traditional tools like troponins and enables the discovery of novel predictors through multi-omics and wearable data integration, supporting dynamic and individualized risk assessment. Despite promising results, most studies remain retrospective or single-center, with limited validation across diverse populations and healthcare environments. Key barriers include algorithm bias, generalizability, regulatory uncertainty, and limited clinician familiarity. Future progress will depend on multicenter trials, federated learning, explainable AI, and integration into existing workflows. In conclusion, AI has the potential to transform cardiovascular care by enabling earlier and more precise diagnosis of IHD and more personalized risk prediction. However, realizing this potential will require careful validation, equitable implementation, and collaboration across disciplines to ensure safe and effective adoption in clinical practice.
Azami et al. (2026) conducted a review in Ischemic heart disease (including acute myocardial infarction). Artificial intelligence (machine learning and deep learning) applied to ECG, cardiac imaging, biomarkers, and risk prediction models vs. Conventional diagnostic methods (standard ECG interpretation, traditional cardiac imaging, standard troponin thresholds, and clinical risk scores) was evaluated on Diagnostic accuracy and risk prediction performance for ischemic heart disease across ECG, imaging, and biomarker domains. Artificial intelligence models enhance early detection and risk prediction of ischemic heart disease across ECG, cardiac imaging, and biomarker modalities compared to conventional diagnostic tools.
Synapse has enriched 10 related papers. Consider them for comparative context: